1
|
Saito S, Ueda J. Preclinical magnetic resonance imaging and spectroscopy in the fields of radiological technology, medical physics, and radiology. Radiol Phys Technol 2024; 17:47-59. [PMID: 38351261 PMCID: PMC10901953 DOI: 10.1007/s12194-024-00785-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2024] [Revised: 01/18/2024] [Accepted: 01/20/2024] [Indexed: 03/01/2024]
Abstract
Magnetic resonance imaging (MRI) is an indispensable diagnostic imaging technique used in the clinical setting. MRI is advantageous over X-ray and computed tomography (CT), because the contrast provided depends on differences in the density of various organ tissues. In addition to MRI systems in hospitals, more than 100 systems are used for research purposes in Japan in various fields, including basic scientific research, molecular and clinical investigations, and life science research, such as drug discovery, veterinary medicine, and food testing. For many years, additional preclinical imaging studies have been conducted in basic research in the fields of radiation technology, medical physics, and radiology. The preclinical MRI research includes studies using small-bore and whole-body MRI systems. In this review, we focus on the animal study using small-bore MRI systems as "preclinical MRI". The preclinical MRI can be used to elucidate the pathophysiology of diseases and for translational research. This review will provide an overview of previous preclinical MRI studies such as brain, heart, and liver disease assessments. Also, we provide an overview of the utility of preclinical MRI studies in radiological physics and technology.
Collapse
Affiliation(s)
- Shigeyoshi Saito
- Department of Medical Physics and Engineering, Area of Medical Imaging Technology and Science, Division of Health Sciences, Osaka University Graduate School of Medicine, Suita, Osaka, 560-0871, Japan.
- Department of Advanced Medical Technologies, National Cerebral and Cardiovascular Center Research Institute, Suita, 564-8565, Japan.
| | - Junpei Ueda
- Department of Medical Physics and Engineering, Area of Medical Imaging Technology and Science, Division of Health Sciences, Osaka University Graduate School of Medicine, Suita, Osaka, 560-0871, Japan
| |
Collapse
|
2
|
Karna B, Pellegata NS, Mohr H. Animal and Cell Culture Models of PPGLs - Achievements and Limitations. Horm Metab Res 2024; 56:51-64. [PMID: 38171372 DOI: 10.1055/a-2204-4549] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/05/2024]
Abstract
Research on rare tumors heavily relies on suitable models for basic and translational research. Paragangliomas (PPGL) are rare neuroendocrine tumors (NET), developing from adrenal (pheochromocytoma, PCC) or extra-adrenal (PGL) chromaffin cells, with an annual incidence of 2-8 cases per million. While most PPGL cases exhibit slow growth and are primarily treated with surgery, limited systemic treatment options are available for unresectable or metastatic tumors. Scarcity of appropriate models has hindered PPGL research, preventing the translation of omics knowledge into drug and therapy development. Human PPGL cell lines are not available, and few animal models accurately replicate the disease's genetic and phenotypic characteristics. This review provides an overview of laboratory models for PPGLs, spanning cellular, tissue, organ, and organism levels. We discuss their features, advantages, and potential contributions to diagnostics and therapeutics. Interestingly, it appears that in the PPGL field, disease models already successfully implemented in other cancers have not been fully explored.
Collapse
Affiliation(s)
- Bhargavi Karna
- Institute for Diabetes and Cancer, Helmholtz Center Munich - German Research Center for Environmental Health, Neuherberg, Germany
| | - Natalia Simona Pellegata
- Institute for Diabetes and Cancer, Helmholtz Center Munich - German Research Center for Environmental Health, Neuherberg, Germany
- Department of Biology and Biotechnology, University of Pavia, Pavia, Italy
| | - Hermine Mohr
- Institute for Diabetes and Cancer, Helmholtz Center Munich - German Research Center for Environmental Health, Neuherberg, Germany
| |
Collapse
|
3
|
Grashei M, Wodtke P, Skinner JG, Sühnel S, Setzer N, Metzler T, Gulde S, Park M, Witt D, Mohr H, Hundshammer C, Strittmatter N, Pellegata NS, Steiger K, Schilling F. Simultaneous magnetic resonance imaging of pH, perfusion and renal filtration using hyperpolarized 13C-labelled Z-OMPD. Nat Commun 2023; 14:5060. [PMID: 37604826 PMCID: PMC10442412 DOI: 10.1038/s41467-023-40747-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2022] [Accepted: 08/09/2023] [Indexed: 08/23/2023] Open
Abstract
pH alterations are a hallmark of many pathologies including cancer and kidney disease. Here, we introduce [1,5-13C2]Z-OMPD as a hyperpolarized extracellular pH and perfusion sensor for MRI which allows to generate a multiparametric fingerprint of renal disease status and to detect local tumor acidification. Exceptional long T1 of two minutes at 1 T, high pH sensitivity of up to 1.9 ppm per pH unit and suitability of using the C1-label as internal frequency reference enables pH imaging in vivo of three pH compartments in healthy rat kidneys. Spectrally selective targeting of both 13C-resonances enables simultaneous imaging of perfusion and filtration in 3D and pH in 2D within one minute to quantify renal blood flow, glomerular filtration rates and renal pH in healthy and hydronephrotic kidneys with superior sensitivity compared to clinical routine methods. Imaging multiple biomarkers within a single session renders [1,5-13C2]Z-OMPD a promising new hyperpolarized agent for oncology and nephrology.
Collapse
Affiliation(s)
- Martin Grashei
- Department of Nuclear Medicine, TUM School of Medicine, Klinikum rechts der Isar, Technical University of Munich, D-81675, Munich, Germany
| | - Pascal Wodtke
- Department of Nuclear Medicine, TUM School of Medicine, Klinikum rechts der Isar, Technical University of Munich, D-81675, Munich, Germany
| | - Jason G Skinner
- Department of Nuclear Medicine, TUM School of Medicine, Klinikum rechts der Isar, Technical University of Munich, D-81675, Munich, Germany
| | - Sandra Sühnel
- Department of Nuclear Medicine, TUM School of Medicine, Klinikum rechts der Isar, Technical University of Munich, D-81675, Munich, Germany
| | - Nadine Setzer
- Department of Nuclear Medicine, TUM School of Medicine, Klinikum rechts der Isar, Technical University of Munich, D-81675, Munich, Germany
| | - Thomas Metzler
- Comparative Experimental Pathology (CEP), Institute of Pathology, School of Medicine, Technical University of Munich, D-81675, Munich, Germany
| | - Sebastian Gulde
- Institute for Diabetes and Cancer, Helmholtz Zentrum München, D-85764, Neuherberg, Germany
| | - Mihyun Park
- Department of Biosciences, TUM School of Natural Sciences, Technical University of Munich, D-85748, Garching, Germany
| | - Daniela Witt
- Department of Biosciences, TUM School of Natural Sciences, Technical University of Munich, D-85748, Garching, Germany
| | - Hermine Mohr
- Institute for Diabetes and Cancer, Helmholtz Zentrum München, D-85764, Neuherberg, Germany
| | - Christian Hundshammer
- Department of Nuclear Medicine, TUM School of Medicine, Klinikum rechts der Isar, Technical University of Munich, D-81675, Munich, Germany
| | - Nicole Strittmatter
- Department of Biosciences, TUM School of Natural Sciences, Technical University of Munich, D-85748, Garching, Germany
| | - Natalia S Pellegata
- Institute for Diabetes and Cancer, Helmholtz Zentrum München, D-85764, Neuherberg, Germany
- Department of Biology and Biotechnology, University of Pavia, I-27100, Pavia, Italy
| | - Katja Steiger
- Comparative Experimental Pathology (CEP), Institute of Pathology, School of Medicine, Technical University of Munich, D-81675, Munich, Germany
| | - Franz Schilling
- Department of Nuclear Medicine, TUM School of Medicine, Klinikum rechts der Isar, Technical University of Munich, D-81675, Munich, Germany.
- Munich Institute of Biomedical Engineering, Technical University of Munich, D-85748, Garching, Germany.
- German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Center (DKFZ), D-69120, Heidelberg, Germany.
| |
Collapse
|